A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients

NCT05662956 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax in combination with azacitidine and CAG

Sponsor

Hematology department of the 920th hospital